India to Finland: Acetylsalicylic Export Trade Route

To import acetylsalicylic acid formulations into Finland, the following approvals and registrations are necessary:

• Marketing Authorization: A valid marketing authorization is mandatory for all medicinal products intended for the Finnish market. This authorization can be obtained through the centralized procedure via the EMA or through national procedures coordinated by Fimea.

• Dossier Submission: Applicants must submit a comprehensive dossier in the Common Technical Document (CTD) or electronic CTD (eCTD) format. This dossier should include detailed information on the product's quality, safety, and efficacy.

• Approval Timelines: The approval process duration varies based on the chosen procedure. The centralized procedure typically takes approximately 210 days, excluding clock stops for additional information requests. National procedures may have different timelines.

• Product Registration Fees: Fees are applicable for both centralized and national procedures. The exact amounts depend on the specific application and are subject to periodic updates.

• GMP Inspection Requirements: Manufacturing facilities, including those in India, must comply with EU Good Manufacturing Practice (GMP) standards. Compliance is verified through inspections conducted by EU authorities or recognized via Mutual Recognition Agreements (MRAs).

Indian exporters of acetylsalicylic acid formulations must meet the following GMP certifications and standards:

• GMP Certification: Manufacturers must hold a GMP certificate issued by an EU authority or a competent authority from a country with an MRA with the EU. This certification confirms adherence to EU GMP standards.

• Approved Facilities: Only manufacturing sites that have undergone successful GMP inspections and are listed in the EudraGMDP database are approved to export to the EU.

• Recent Inspections and Regulatory Actions: EU authorities regularly inspect Indian pharmaceutical facilities. For instance, in August 2016, the German authority issued a GMP Non-Compliance Statement for an Indian API manufacturer due to significant deficiencies.

Several regulatory changes and developments have occurred in the past 18 months affecting Indian pharmaceutical exports to Finland:

• Revision of GMP Guidelines: In February 2026, the EMA initiated public consultations on revising Annex 6 (Manufacture of Medicinal Gases) and Annex 15 (Qualification and Validation) of the GMP guidelines to reflect current industry practices and technological advancements.

• Implementation of IVD Regulation: In May 2022, the EU's In Vitro Diagnostic Regulation (IVDR) (2017/746) became fully applicable, aiming to enhance patient safety and consider technological developments.

• Enhanced Quality Assurance Measures: Following incidents involving substandard products, regulatory bodies have intensified scrutiny on pharmaceutical imports, emphasizing rigorous quality management and compliance with GMP standards.

These developments underscore the importance for Indian exporters to stay informed and compliant with evolving EU and Finnish regulatory requirements to ensure uninterrupted market access.

In 2024, Finland's pharmaceutical market was valued at approximately €2.5 billion, with cardiovascular medications, including acetylsalicylic acid formulations, accounting for around 15% of this total. This places the market for acetylsalicylic acid formulations at an estimated €375 million. The demand for these formulations is primarily driven by the country's aging population, with over 22% of Finns aged 65 and above, leading to a higher prevalence of cardiovascular diseases. Additionally, Finland's universal healthcare system ensures widespread access to essential medications, further bolstering demand. While Finland has a robust pharmaceutical manufacturing sector, it relies on imports to meet the full spectrum of its acetylsalicylic acid formulation needs, with domestic production focusing on specific formulations and dosages.

Finland, as a member of the European Union, applies a 0% Most-Favored-Nation (MFN) import duty rate on pharmaceutical products under HS code 30049099, which includes acetylsalicylic acid formulations. This zero-tariff policy is part of the EU's commitment to facilitating access to essential medicines. Additionally, Finland imposes a Value Added Tax (VAT) of 10% on pharmaceutical products, which is lower than the standard VAT rate, reflecting the essential nature of these goods. There are no specific Free Trade Agreements (FTAs) between India and Finland that alter this tariff structure, nor are there any anti-dumping duties currently in place affecting the import of acetylsalicylic acid formulations from India.

India is a significant supplier of acetylsalicylic acid formulations to Finland, accounting for 14.7% of Finland's total imports in this category, with a trade value of $0.6 million USD. The primary Indian exporters are Dr. Reddy's Laboratories Limited, contributing $0.4 million, and Dr. Reddy's Laboratories Ltd, contributing $0.2 million. The main Finnish importer is Orion Corporation, which accounts for the entire $0.6 million import value. Other major countries supplying acetylsalicylic acid formulations to Finland include Germany, Switzerland, and the Netherlands, which collectively account for approximately 60% of Finland's imports in this category. India's competitive advantage lies in its cost-effective manufacturing processes, allowing it to offer acetylsalicylic acid formulations at prices approximately 20% lower than those from European manufacturers. This pricing strategy, combined with India's adherence to international quality standards, positions it as a competitive player in Finland's pharmaceutical import market.

India has solidified its position as a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. This extensive manufacturing capability encompasses a wide range of finished dosage forms, including tablets, capsules, syrups, and injections. The country's cost-effective production processes, driven by economies of scale and a skilled workforce, enable the delivery of high-quality formulations at competitive prices. As of 2024, India boasts 752 FDA-approved, 2,050 WHO-GMP-certified, and 286 EDQM-approved manufacturing facilities, underscoring its commitment to stringent quality standards.

When evaluating the sourcing of Acetylsalicylic formulations, India offers a compelling balance of cost and quality. Indian manufacturers provide these formulations at a lower price point compared to European counterparts, without compromising on quality. The country's adherence to international regulatory standards, evidenced by numerous FDA and WHO-GMP certifications, ensures acceptance in markets like Finland. While China is a significant player in generic formulations, India's established track record in supplying to regulated markets, including the EU, positions it favorably in terms of quality perception and supply reliability.

The India-Finland supply chain for Acetylsalicylic formulations has demonstrated reliability, supported by India's substantial manufacturing capacity and advanced packaging capabilities. The country's pharmaceutical sector has experienced consistent growth, with exports increasing at 9%—nearly double the global average—as of February 2025. This growth reflects India's ability to meet global demand effectively. The regulatory compliance track record of Indian manufacturers has also improved, with US FDA Official Action Indicated (OAI) instances dropping by 50% over the past decade. While no significant supply disruptions have been reported recently, continuous monitoring of manufacturers' capacity and compliance is advisable to ensure sustained reliability.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Acetylsalicylic formulations.

• Establish Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Agree on Favorable Payment Terms: Standard payment terms in India-Finland pharmaceutical trade often include a 30-60 day credit period; ensure terms are clearly defined and mutually beneficial.

• Conduct Thorough Supplier Qualification: Perform comprehensive audits of potential suppliers, focusing on regulatory compliance, manufacturing capabilities, and quality control processes to ensure alignment with your standards.

• Monitor Regulatory Compliance: Regularly review suppliers' adherence to international regulatory standards to maintain product quality and facilitate smooth market entry in Finland.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified standards.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory compliance.

3. GMP Certificate: Issued by the relevant regulatory authority, confirming the manufacturing facility complies with GMP standards.

4. Stability Data: Includes data from stability studies conducted under International Council for Harmonisation (ICH) guidelines, demonstrating the product's shelf life and storage conditions.

5. Batch Records: Detailed documentation of the manufacturing process for each batch, ensuring consistency and traceability.

6. Drug Master File (DMF): Comprehensive document submitted to regulatory authorities, detailing the manufacturing process, controls, and specifications.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organisation (CDSCO), indicating the product is approved for sale in India and can be legally exported.

8. Insurance Certificates: Proof of liability insurance coverage, ensuring protection against potential claims related to product quality or safety.

By adhering to this structured approach, Finnish companies can effectively qualify Indian suppliers of acetylsalicylic acid formulations, ensuring product quality, regulatory compliance, and supply chain reliability.